Clinical Trial Update: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Incyte Corporation | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-04